Tuesday, July 26, 2016 8:41:23 AM
2nd Quarter Earnings
Looks pretty good, Reuters is reporting revenue of $63.1 million, $2 million above estimates, just like I predicted. Adjusted revenue of 4 cents/share is 1 cent better than estimates.
* Neogenomics reports 159% revenue growth to $63.1 million and strong gains in profitability in the second quarter of 2016
* Q2 adjusted earnings per share $0.04
* Q2 loss per share $0.07
* Q2 revenue $63.1 million versus i/b/e/s view $61.1 million
* Q2 earnings per share view $0.03 -- Thomson Reuters I/B/E/S
Time will tell how the street views the results. Looking forward to the CC.
GLTA
Looks pretty good, Reuters is reporting revenue of $63.1 million, $2 million above estimates, just like I predicted. Adjusted revenue of 4 cents/share is 1 cent better than estimates.
* Neogenomics reports 159% revenue growth to $63.1 million and strong gains in profitability in the second quarter of 2016
* Q2 adjusted earnings per share $0.04
* Q2 loss per share $0.07
* Q2 revenue $63.1 million versus i/b/e/s view $61.1 million
* Q2 earnings per share view $0.03 -- Thomson Reuters I/B/E/S
Time will tell how the street views the results. Looking forward to the CC.
GLTA
Recent NEO News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 08:19:44 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 08:05:31 PM
- NeoGenomics to Participate in Upcoming Investor Conferences • Business Wire • 05/15/2026 01:05:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/13/2026 09:30:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2026 08:19:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2026 08:18:56 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/07/2026 08:34:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/05/2026 08:27:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/05/2026 08:27:19 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/30/2026 03:41:23 PM
- NeoGenomics Shares Jump on Earnings and Analyst Upgrades • IH Market News • 04/29/2026 11:27:26 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/28/2026 09:01:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 08:59:44 PM
- NeoGenomics Reports First Quarter 2026 Results • Business Wire • 04/28/2026 08:05:00 PM
- NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration • Business Wire • 04/23/2026 11:05:00 AM
- NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026 • Business Wire • 04/13/2026 11:05:00 AM
- NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026 • Business Wire • 04/07/2026 11:05:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/06/2026 08:26:16 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/06/2026 08:25:01 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/06/2026 08:22:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:39:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:38:47 PM
- NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling • Business Wire • 03/16/2026 11:05:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 11:16:42 PM
